Cardiovascular disease involves cellular processes that unfold over decades — among them, the gradual decline of mitochondrial function in heart muscle cells. As researchers search for interventions that work at this level, urolithin A has emerged as a compound of genuine scientific interest. Unlike many supplements that lack mechanistic rationale, urolithin A has a plausible and increasingly documented way of acting on the cellular machinery that keeps cardiac cells energized.
Urolithin A is not consumed directly from food. It is produced by gut bacteria when they break down ellagitannins — polyphenols found in pomegranates, berries, and walnuts. Because only certain gut microbiome profiles can make this conversion efficiently, the amount of urolithin A a person produces from diet varies considerably from person to person. Researchers are now studying whether supplemental urolithin A can deliver cardiovascular benefits more consistently, and early human trials are beginning to provide initial answers.
Key Takeaways
- Urolithin A activates mitophagy — the selective removal of damaged mitochondria — a mechanism directly relevant to the high energy demands of cardiac muscle [1].
- Preclinical studies found urolithin A promotes atherosclerotic plaque stability and reduces inflammation in animal models of cardiovascular disease [2].
- The only randomized trial in patients with diagnosed heart disease — 10 people with heart failure and reduced ejection fraction — found no effect of urolithin A on any echocardiographic measure, or on pro-BNP, glucose or CRP [3]. A separate human study reported improvements in cardiovascular biomarkers in people without heart failure [4].
- Mediterranean diet polyphenol patterns — which include urolithin A precursors from pomegranates, berries, and nuts — are associated with lower cardiovascular disease risk in large epidemiological data [5].
- Most human evidence involves biomarker changes rather than clinical outcomes; large, long-term trials measuring actual cardiovascular events have not yet been published.
Why the Heart Depends on Healthy Mitochondria
Cardiac muscle cells beat roughly 100,000 times per day and cannot rest. To sustain this continuous output, heart cells rely almost entirely on mitochondria — organelles that generate ATP through oxidative phosphorylation. A single cardiomyocyte may contain thousands of mitochondria, and these organelles occupy a substantial fraction of the cell’s volume. When mitochondria accumulate damage from oxidative stress, age, or disease, the heart’s ability to generate energy efficiently declines [6].
Researchers studying heart disease have identified mitochondrial dysfunction as a consistent feature across several cardiac conditions, including heart failure. Poor mitochondrial quality control — the processes that clear damaged mitochondria and generate new, healthy ones — has been proposed as a target for therapeutic intervention [7]. This is where urolithin A’s primary mechanism becomes cardiovascularly relevant.
Urolithin A and Mitophagy: Clearing Damaged Mitochondria
Mitophagy is the selective process by which cells identify and remove damaged or dysfunctional mitochondria before they can cause wider cellular harm. Urolithin A is one of the few orally available compounds shown to activate this pathway in human tissue. Research comparing urolithin A to other autophagy-inducing compounds has clarified that it plays a distinct role specifically in mitophagy — the mitochondria-targeted form of autophagy — rather than generalized cellular cleanup [1].
By stimulating mitophagy, urolithin A may help cardiac cells maintain a healthier pool of mitochondria over time. This is not a rapid pharmacological effect but rather support for a natural cellular maintenance process that normally declines with age. A systematic review of urolithin A studies in humans found improvements in mitochondrial health markers among the more consistent findings across trials [8].
Atherosclerosis: Preclinical Evidence for Plaque Stability
Atherosclerosis — the buildup of plaques inside arterial walls — is a primary driver of heart attack and stroke. Plaque stability, not just plaque size, determines much of the risk: plaques that rupture trigger clot formation and acute events. In a preclinical study using apolipoprotein E-deficient mice, a standard model for atherosclerosis research, urolithin A was found to promote atherosclerotic plaque stability while limiting both inflammation and elevated cholesterol levels [2]. The researchers proposed that urolithin A’s anti-inflammatory properties contribute to this stabilizing effect.
It is important to note that this evidence comes from animal models. Whether the same plaque-stabilizing effects occur in humans at supplemental doses is not yet established. Preclinical findings of this type generate hypotheses for human trials rather than confirm clinical outcomes.
The Gut-Heart Connection
Urolithin A sits at the intersection of two active research areas: gut microbiome health and cardiovascular disease. The gut microbiome influences cardiac function through multiple pathways, including production of metabolites that circulate to the heart, regulation of systemic inflammation, and epigenetic changes in cardiac tissue [9]. Because urolithin A is itself a gut-derived metabolite, understanding this connection matters for how dietary choices might influence heart health over the long term.
Epidemiological data from the PREDIMED trial offers relevant context. Researchers found that a urinary polyphenol signature associated with the Mediterranean diet — a dietary pattern that promotes urolithin A production given its inclusion of fruits, nuts, and legumes — was associated with lower cardiovascular disease risk [5]. While this does not prove that urolithin A specifically drives this association (other polyphenols and dietary factors are also involved), it suggests that populations with the dietary habits that foster urolithin A production tend to have better cardiovascular outcomes in observational data.
Human Clinical Evidence: What Trials Have Found
Moving from mechanisms and animal models to human trials is the critical step in evaluating any compound’s real-world relevance. A 2025 study published in iScience demonstrated both preclinical cardioprotection and improvements in human cardiovascular health biomarkers following urolithin A supplementation [4]. This type of study — combining animal mechanistic data with a human biomarker component — represents an important step in building the translational case for urolithin A in heart health.
A randomized, double-blind, crossover, placebo-controlled clinical trial has evaluated urolithin A specifically in heart failure patients with reduced ejection fraction, a population with significant unmet need for treatments that support cardiac energy metabolism [3]. That trial did not find a benefit. Ten patients received 500 mg twice daily across two four-week periods, and urolithin A produced no significant change in left ventricular ejection fraction, LVEDD, LVESV or TAPSE, and no change in pro-BNP, glucose or CRP. The one measure that moved was HDL cholesterol, which rose by about 6.5 mg/dL (p = 0.026); other lipid measures were unchanged. The authors concluded that the results do not support a positive effect of urolithin A on echocardiographic and biochemical indices in this population, and called for studies using higher doses and longer supplementation. Crossover designs, in which participants receive both treatment and placebo in sequence, are particularly valuable for controlling individual variation, which makes a null result in this design harder to dismiss as noise. A scoping review of urolithin A research also identified cardiovascular aging as one of the key areas where the compound shows potential [10].
Across the human evidence to date, urolithin A has not been associated with serious adverse effects at studied doses. Biomarker improvements have been reported in generally healthy adults, but the single randomized trial conducted in patients with diagnosed heart disease was negative [3] — a distinction worth keeping in view, because supporting a biomarker in a healthy person is not the same as improving an established cardiac condition. However, most human trials remain relatively short in duration and modest in size. Longer-term data tracking actual cardiovascular events rather than surrogate biomarkers are still needed.
Understanding the Limits of Current Evidence
The cardiovascular research on urolithin A is genuinely promising, but it is early-stage. Much of the mechanistic work has been conducted in cell cultures or animal models, and preclinical findings do not always translate into the same effects in humans. The atherosclerosis data [2] and much of the mitochondrial quality control pathway research [7] falls into this preclinical category. Human trials are now underway or recently completed, but the field has not yet produced large, long-term studies measuring clinical endpoints such as heart attack, stroke, or cardiovascular mortality.
Individual variation in gut microbiome composition also complicates the picture for dietary urolithin A. Not everyone converts polyphenol-rich foods to urolithin A efficiently — the capacity depends on which bacterial species are present in a given person’s gut. Supplemental urolithin A bypasses this conversion step, potentially making the compound more accessible regardless of microbiome profile. Whether supplemental and microbiome-derived urolithin A behave identically in the body remains an open research question.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day — The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10) — established clinical-supplement brand, third-party tested. - ProHealth Longevity Urolithin A
capsules, 500 mg — Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg — Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The evidence reviewed here spans preclinical studies, early-stage clinical trials, and epidemiological data — it does not yet establish that urolithin A supplements prevent heart disease or improve outcomes in established cardiovascular conditions. Anyone with existing heart disease, taking cardiac medications, or considering urolithin A supplementation should consult a qualified healthcare provider before starting.
Frequently Asked Questions
What is the connection between urolithin A and heart health?
Urolithin A stimulates mitophagy — the process by which cells clear out damaged mitochondria and maintain a healthier pool. Because the heart is one of the most mitochondria-dependent organs in the body, this mechanism is particularly relevant to cardiac function [6]. Preclinical and early human data suggest urolithin A may support cardiovascular biomarkers and plaque stability [4].
Has urolithin A been tested in people with heart disease?
Yes, and the result was negative. A randomized, double-blind, crossover, placebo-controlled trial gave 500 mg twice daily to 10 patients with heart failure and reduced ejection fraction, and found no significant effect on ejection fraction or any other echocardiographic measure, or on pro-BNP, glucose or CRP [3]. HDL cholesterol rose modestly. The authors concluded the findings do not support a positive effect in this population. Urolithin A should not be regarded as a treatment for heart failure.
Does eating a Mediterranean diet increase urolithin A levels?
The Mediterranean diet is rich in polyphenol-containing foods — pomegranates, berries, walnuts, legumes — that gut bacteria can convert into urolithin A. A large analysis from the PREDIMED trial found that a urinary polyphenol signature consistent with the Mediterranean diet was associated with lower cardiovascular disease risk [5]. However, individual ability to convert dietary polyphenols to urolithin A varies considerably based on gut microbiome composition, which is why supplemental forms are also being studied.
What does urolithin A do to atherosclerotic plaques?
In apolipoprotein E-deficient mice — a standard preclinical model for atherosclerosis — urolithin A was found to promote plaque stability while reducing both inflammation and hypercholesteremia [2]. Plaque stability matters because plaques that rupture are a primary cause of heart attacks and strokes. This evidence is preclinical only and has not yet been confirmed in human arterial tissue.
Is urolithin A different from other mitochondria supplements?
Urolithin A has a specific mechanism — it activates mitophagy to selectively remove damaged mitochondria — which is distinct from compounds that provide mitochondrial nutrients or cofactors [1]. Mitophagy clears out dysfunctional organelles before they can damage cells further, functioning more like cellular maintenance than a direct energy boost. Research has confirmed that urolithin A’s mitophagy role is meaningfully distinct from other autophagy-promoting compounds studied alongside it.
How long would someone need to take urolithin A to see cardiovascular effects?
Human trials have generally run for weeks to months, and improvements in mitochondrial health markers and cardiovascular biomarkers have been observed within those timeframes [8]. However, the underlying mechanisms — mitophagy, inflammation reduction, plaque stabilization — are slow biological processes rather than acute effects. There is no established dosing duration for cardiovascular benefit, and this question should be discussed with a healthcare provider who knows an individual’s full health picture.
References
- Borsky P et al. Distinct roles of urolithin A and spermidine in mitophagy and autophagy: implications for dietary supplementation. Nutrition research reviews (2025). PMID 41404767
- Xu MY et al. Urolithin A promotes atherosclerotic plaque stability by limiting inflammation and hypercholesteremia in Apolipoprotein E-deficient mice. Acta pharmacologica Sinica (2024). PMID 38886550
- Jamialahmadi T et al. Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial. Reviews on recent clinical trials (2024). PMID 38415449
- Liu S et al. Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers. iScience (2025). PMID 40034121
- Domínguez-López I et al. Urinary polyphenol signature of the Mediterranean diet is associated with lower cardiovascular disease risk: the PREDIMED trial. BMC medicine (2025). PMID 41408634
- Marei HE et al. Mitochondria at the heart of aging: structure, function, and failure. Journal of translational medicine (2026). PMID 42032617
- Oh CM et al. Mitochondrial Quality Control in the Heart: New Drug Targets for Cardiovascular Disease. Korean circulation journal (2020). PMID 32216174
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
- Song J et al. The gut-heart dialogue: an epigenetic perspective on myocardial infarction. NPJ biofilms and microbiomes (2026). PMID 41927585
- Kothe B et al. Urolithin A as a Potential Agent for Prevention of Age-Related Disease: A Scoping Review. Cureus (2023). PMID 37637627
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.